References:
[1]. Somer, T. and S.M. Finegold, Vasculitides associated with infections, immunization, and antimicrobial drugs. Clin Infect Dis, 1995. 20(4): p. 1010-36.
[2]. Kallenberg, C.G., The role of bacterial infections for the initiation and exacerbation of systemic vasculitis. Autoimmun Rev, 2004. 3 Suppl 1: p. S45-7.
[3]. Robson, J.C., et al., 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Ann Rheum Dis, 2022. 81(3): p. 315-320.
[4]. Nakamura, Y., et al., Granulomatosis with Polyangiitis following COVID-19 in an Adolescent. Intern Med, 2023. 62(4): p. 589-593.
[5]. Weynand, M., et al., A case of left foot drop as initial symptom of granulomatosis with polyangiitis: Triggered by COVID-19 disease? Clin Case Rep, 2022. 10(10): p. e6418.
[6]. Selvaraj, V., et al., COVID-19-induced granulomatosis with polyangiitis. BMJ Case Rep, 2021. 14(3).
[7]. Lind, E., A. Jameson and E. Kurban, Fulminant granulomatosis with polyangiitis presenting with diffuse alveolar haemorrhage following COVID-19. BMJ Case Rep, 2021. 14(6).
[8]. Izci, D.T., et al., ANCA-associated vasculitis after COVID-19. Rheumatol Int, 2021. 41(8): p. 1523-1529.
[9]. Bryant, M.C., L.T. Spencer and A. Yalcindag, A case of ANCA-associated vasculitis in a 16-year-old female following SARS-COV-2 infection and a systematic review of the literature. Pediatr Rheumatol Online J, 2022. 20(1): p. 65.
[10]. Qurratulain, Q., A. Ahmed and Q. Jones, Lesson of the month: Severe granulomatosis with polyangiitis (GPA): a diagnostic challenge during the COVID-19 pandemic. Clin Med (Lond), 2021. 21(1): p. 79-80.
[11]. Bressler, M.Y., et al., New Onset Granulomatosis with Polyangiitis Associated with COVID-19. Case Rep Dermatol Med, 2021. 2021: p. 8877292.
[12]. Giles, T., et al., Life-threatening gastrointestinal haemorrhage requiring surgical resection caused by SARS-CoV-2 induced ANCA associated vasculitis: A case report. Int J Surg Case Rep, 2022. 98: p. 107491.
[13]. Mohammad, A.J., et al., Incidence and survival rates in Wegener’s granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology (Oxford), 2009. 48(12): p. 1560-5.
[14]. Jalalzadeh, M., et al., Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis in a Case of Scleroderma After Recent Diagnosis With COVID-19. Cureus, 2021. 13(1): p. e12485.
[15]. Lutalo, P.M. and D.P. D’Cruz, Diagnosis and classification of granulomatosis with polyangiitis (aka Wegener’s granulomatosis). J Autoimmun, 2014. 48-49: p. 94-8.
[16]. Kawashima, S., et al., MPO-ANCA-positive Microscopic Polyangiitis Following COVID-19 Infection. Intern Med, 2022. 61(4): p. 567-570.
[17]. Shoenfeld, Y., et al., The mosaic of autoimmunity: genetic factors involved in autoimmune diseases–2008. Isr Med Assoc J, 2008. 10(1): p. 3-7.
[18]. Toussirot, E. and J. Roudier, Epstein-Barr virus in autoimmune diseases. Best Pract Res Clin Rheumatol, 2008. 22(5): p. 883-96.
[19]. Gracia-Ramos, A.E., E. Martin-Nares and G. Hernandez-Molina, New Onset of Autoimmune Diseases Following COVID-19 Diagnosis. Cells, 2021. 10(12).
[20]. Allena, N., et al., A Rare Case of SARS-CoV-2-Induced Microscopic Polyangiitis. Cureus, 2021. 13(5): p. e15259.
[21]. Garlapati, P. and A. Qurie, Granulomatosis With Polyangiitis. 2023.
[22]. Lee, L.E., et al., Clinical Significance of Antineutrophil Cytoplasmic Antibody Positivity in Patients Infected with SARS-CoV-2. J Clin Med, 2022. 11(14).
[23]. Wang, Y., et al., Cross-reaction of SARS-CoV antigen with autoantibodies in autoimmune diseases. Cell Mol Immunol, 2004. 1(4): p. 304-7.
[24]. Cartin-Ceba, R., T. Peikert and U. Specks, Pathogenesis of ANCA-associated vasculitis. Curr Rheumatol Rep, 2012. 14(6): p. 481-93.